PolypharmacyNCT06902779
Evaluation of the Impact of a Collaboration Between Hospital and Community Pharmacists at Hospital Discharge
A study testing Support of the hospital pharmacist for the medication management at hospital discharge in people with Polypharmacy, run by Pharmacie des Hopitaux de l'Est Lemanique at 1 site in Switzerland.
Trial summary
The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Polypharmacy
- What is being tested?
- Support of the hospital pharmacist for the medication management at hospital discharge
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Sep 2025to 1 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients admitted to the internal medicine ward for more than 48 hours
- Patients prescribed seven or more drugs at the time of screening
- Patients discharged to home
- Patients able to give informed consent as documented by signature
Who cannot join
- Patient discharged to another hospital, nursing home or rehabilitation clinic
- Refusal of the community pharmacy to participate
- Inability to sign consent and follow the procedures of the study, due to language problems, psychological disorders, dementia, alterations of consciousness and lack of judgement
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Hôpital Riviera-Chablais, Vaud-Valais
Rennaz, Canton of Vaud, 1847
About this study
Official title: Enhanced Collaboration Between Hospital and Community Pharmacists to Improve the Hospital Discharge Process
The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home.
The main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care.
The hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.
- Conditions
- Polypharmacy
- Being tested
- Support of the hospital pharmacist for the medication management at hospital discharge
- Keywords
- transition of care, pharmacists, hospital discharge, collaboration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Support of the hospital pharmacist for the medication management at hospital dischargeOther
- The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns.
| Study group | Role | What they receive |
|---|---|---|
| Control arm | No intervention | Participants in the control arm will benefit from the usual standard of care currently provided in routine clinical practice. Physicians performs medication reconciliation on their own and hand-out the prescription to the patient the day of discharge. The patient then goes to the pharmacy for a classical drug dispensation. |
| Intervention arm | Experimental | Participants in the intervention group will benefit from the hospital pharmacist's support to optimize medication management and ensure a safe and effective discharge process. Receives: Other: Support of the hospital pharmacist for the medication management at hospital discharge |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of drug-related problems on the hospital discharge prescription
Community pharmacists will assess the number of drug-related problems (DRP) on the discharge that they faced when preparing the discharge medication. They will have to use the PharmDISC system, which is a validated tool for referencing drug-related problems faced in the community which was adapted from the drug-related problems classification system of the Pharmaceutical Care Network Europe (PCNE). Community pharmacists will also document the intervention performed for each DRP, and the resolution (yes/no) of the DRP.
Measured: 7 days after hospital discharge
Secondary outcomes (3)
Patient's satisfaction
Patients' satisfaction related to their visit at the pharmacy after hospital discharge will be assessed using a questionnaire. Patients will be contacted via email or telephone
Measured: 7 days after hospital discharge
Community pharmacists' satisfaction
The satisfaction of community pharmacists with the service provided by the hospital pharmacist at patient discharge will be evaluated
Measured: Through study completion, approximately 6 months
30 day readmission rate
Number of participants with hospital emergency department visits and hospital readmission in the same hospital within 30 days of discharge
Measured: 30 days after hospital discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2025
- Study start1 Sep 2025
- Primary completion1 Sep 2026
- Study completion1 Sep 2026
Why it stopped: The trial was stopped prematurely after one year of recruitment because of a combination of slower-than expected enrollment, limited resources, and concerns regarding the feasibility of demonstrating the prespecified treatment effect.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for PolypharmacyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pharmacie des Hopitaux de l'Est Lemanique
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anne-Laure Blanc, PharmD, PhD, Study director, Pharmacie des Hôpitaux de l'Est Lémanique
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06902779
- Sponsor's protocol ID
- ECHOPHARM
- Status last verified
- Sep 2026
- First submitted
- 11 Mar 2025
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data to be shared includes demographic and study outcomes, with a data summary Data will be anonymized and shared in a secure format (CSV)
Publications
Michel B, Hemery M, Rybarczyk-Vigouret MC, Wehrle P, Beck M. Drug-dispensing problems community pharmacists face when patients are discharged from hospitals: a study about 537 prescriptions in Alsace. Int J Qual Health Care. 2016 Dec 1;28(6):779-784. doi: 10.1093/intqhc/mzw111.
PubMed 27655792Braund R, Coulter CV, Bodington AJ, Giles LM, Greig AM, Heaslip LJ, Marshall BJ. Drug related problems identified by community pharmacists on hospital discharge prescriptions in New Zealand. Int J Clin Pharm. 2014 Jun;36(3):498-502. doi: 10.1007/s11096-014-9935-8. Epub 2014 Apr 4.
PubMed 24700340Imfeld-Isenegger TL, Studer H, Ceppi MG, Rosen C, Bodmer M, Beeler PE, Boeni F, Haring AP, Hersberger KE, Lampert ML. Detection and resolution of drug-related problems at hospital discharge focusing on information availability - a retrospective analysis. Z Evid Fortbild Qual Gesundhwes. 2021 Nov;166:18-26. doi: 10.1016/j.zefq.2021.08.004. Epub 2021 Sep 15.
PubMed 34538579Ahmad A, Mast MR, Nijpels G, Elders PJ, Dekker JM, Hugtenburg JG. Identification of drug-related problems of elderly patients discharged from hospital. Patient Prefer Adherence. 2014 Feb 4;8:155-65. doi: 10.2147/PPA.S48357. eCollection 2014.
PubMed 24523581Maes KA, Studer H, Berger J, Hersberger KE, Lampert ML. Documentation of pharmaceutical care: Validation of an intervention oriented classification system. J Eval Clin Pract. 2017 Dec;23(6):1425-1432. doi: 10.1111/jep.12817. Epub 2017 Sep 29.
PubMed 28960678Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016 Apr;41(2):128-44. doi: 10.1111/jcpt.12364. Epub 2016 Feb 23.
PubMed 26913812McCarthy LM, Li S, Fernandes O, Cameron K, Lui P, Wong G, Pariser P, Farrell J, Luke MJ, Guilcher SJT. Enhanced communication between inpatient and community pharmacists to optimize medication management during transitions of care. J Am Pharm Assoc (2003). 2019 Jan-Feb;59(1):79-86.e1. doi: 10.1016/j.japh.2018.09.006. Epub 2018 Nov 13.
PubMed 30446423Bruhwiler LD, Hersberger KE, Lutters M. Hospital discharge: What are the problems, information needs and objectives of community pharmacists? A mixed method approach. Pharm Pract (Granada). 2017 Jul-Sep;15(3):1046. doi: 10.18549/PharmPract.2017.03.1046. Epub 2017 Aug 25.
PubMed 28943987Grandchamp S, Blanc AL, Roussel M, Tagan D, Sautebin A, Dobrinas-Bonazzi M, Widmer N. Pharmaceutical Interventions on Hospital Discharge Prescriptions: Prospective Observational Study Highlighting Challenges for Community Pharmacists. Drugs Real World Outcomes. 2022 Jun;9(2):253-261. doi: 10.1007/s40801-021-00288-x. Epub 2021 Dec 31.
PubMed 34971408Redmond P, Grimes TC, McDonnell R, Boland F, Hughes C, Fahey T. Impact of medication reconciliation for improving transitions of care. Cochrane Database Syst Rev. 2018 Aug 23;8(8):CD010791. doi: 10.1002/14651858.CD010791.pub2.
PubMed 30136718Ensing HT, Stuijt CC, van den Bemt BJ, van Dooren AA, Karapinar-Carkit F, Koster ES, Bouvy ML. Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review. J Manag Care Spec Pharm. 2015 Aug;21(8):614-36. doi: 10.18553/jmcp.2015.21.8.614.
PubMed 26233535Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016 Feb 23;6(2):e010003. doi: 10.1136/bmjopen-2015-010003.
PubMed 26908524Villeneuve Y, Courtemanche F, Firoozi F, Gilbert S, Desbiens MP, Desjardins A, Dinh C, LeBlanc VC, Attia A. Impact of pharmacist interventions during transition of care in older adults to reduce the use of healthcare services: A scoping review. Res Social Adm Pharm. 2021 Aug;17(8):1361-1372. doi: 10.1016/j.sapharm.2020.11.006. Epub 2020 Nov 13.
PubMed 33250364Banholzer S, Dunkelmann L, Haschke M, Derungs A, Exadaktylos A, Krahenbuhl S, Liakoni E. Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission. Swiss Med Wkly. 2021 Jan 20;151:w20400. doi: 10.4414/smw.2021.20400. eCollection 2021 Jan 18.
PubMed 33516159Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003 Feb 4;138(3):161-7. doi: 10.7326/0003-4819-138-3-200302040-00007.
PubMed 12558354
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhanced Collaboration Between Hospital and Community Pharmacists to Improve the Hospital Discharge Process
- ClinicalTrials.gov ID
- NCT06902779
- Acronym / sponsor ID
- ECHOPHARM
- Conditions
- Polypharmacy
- Keywords
- transition of care, pharmacists, hospital discharge, collaboration
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The trial was stopped prematurely after one year of recruitment because of a combination of slower-than expected enrollment, limited resources, and concerns regarding the feasibility of demonstrating the prespecified treatment effect.
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Pharmacie des Hopitaux de l'Est LemaniqueUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 1 Sep 2026 (actual)
- Study completion
- 1 Sep 2026 (actual)
- First posted
- 30 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home.
The main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care.
The hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control arm | No intervention | –Participants in the control arm will benefit from the usual standard of care currently provided in routine clinical practice. Physicians performs medication reconciliation on their own and hand-out the prescription to the patient the day of discharge. The patient then goes to the pharmacy for a classical drug dispensation. |
| Intervention arm | Experimental | Other: Support of the hospital pharmacist for the medication management at hospital dischargeParticipants in the intervention group will benefit from the hospital pharmacist's support to optimize medication management and ensure a safe and effective discharge process. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients admitted to the internal medicine ward for more than 48 hours
- Patients prescribed seven or more drugs at the time of screening
- Patients discharged to home
- Patients able to give informed consent as documented by signature
Key exclusion criteria (3 listed)
- Patient discharged to another hospital, nursing home or rehabilitation clinic
- Refusal of the community pharmacy to participate
- Inability to sign consent and follow the procedures of the study, due to language problems, psychological disorders, dementia, alterations of consciousness and lack of judgement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Support of the hospital pharmacist for the medication management at hospital discharge1) The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns. | Other | Intervention arm |
Primary outcome
Number of drug-related problems on the hospital discharge prescription
Time frame: 7 days after hospital discharge
Community pharmacists will assess the number of drug-related problems (DRP) on the discharge that they faced when preparing the discharge medication. They will have to use the PharmDISC system, which is a validated tool for referencing drug-related problems faced in the community which was adapted from the drug-related problems classification system of the Pharmaceutical Care Network Europe (PCNE). Community pharmacists will also document the intervention performed for each DRP, and the resolution (yes/no) of the DRP.
3 secondary outcomes
Patient's satisfaction
Time frame: 7 days after hospital discharge
Community pharmacists' satisfaction
Time frame: Through study completion, approximately 6 months
30 day readmission rate
Time frame: 30 days after hospital discharge
Results and safety
The study was stopped early (reason given: The trial was stopped prematurely after one year of recruitment because of a combination of slower-than expected enrollment, limited resources, and concerns regarding the feasibility of demonstrating the prespecified treatment effect.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Background: PubMed 27655792Michel B, Hemery M, Rybarczyk-Vigouret MC, Wehrle P, Beck M. Drug-dispensing problems community pharmacists face when patients are discharged from hospitals: a study about 537 prescriptions in Alsace. Int J Qual Health Care. 2016 Dec 1;28(6):779-784. doi: 10.1093/intqhc/mzw111.
- Background: PubMed 24700340Braund R, Coulter CV, Bodington AJ, Giles LM, Greig AM, Heaslip LJ, Marshall BJ. Drug related problems identified by community pharmacists on hospital discharge prescriptions in New Zealand. Int J Clin Pharm. 2014 Jun;36(3):498-502. doi: 10.1007/s11096-014-9935-8. Epub 2014 Apr 4.
- Background: PubMed 34538579Imfeld-Isenegger TL, Studer H, Ceppi MG, Rosen C, Bodmer M, Beeler PE, Boeni F, Haring AP, Hersberger KE, Lampert ML. Detection and resolution of drug-related problems at hospital discharge focusing on information availability - a retrospective analysis. Z Evid Fortbild Qual Gesundhwes. 2021 Nov;166:18-26. doi: 10.1016/j.zefq.2021.08.004. Epub 2021 Sep 15.
- Background: PubMed 24523581Ahmad A, Mast MR, Nijpels G, Elders PJ, Dekker JM, Hugtenburg JG. Identification of drug-related problems of elderly patients discharged from hospital. Patient Prefer Adherence. 2014 Feb 4;8:155-65. doi: 10.2147/PPA.S48357. eCollection 2014.
- Background: PubMed 28960678Maes KA, Studer H, Berger J, Hersberger KE, Lampert ML. Documentation of pharmaceutical care: Validation of an intervention oriented classification system. J Eval Clin Pract. 2017 Dec;23(6):1425-1432. doi: 10.1111/jep.12817. Epub 2017 Sep 29.
- Background: PubMed 26913812Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016 Apr;41(2):128-44. doi: 10.1111/jcpt.12364. Epub 2016 Feb 23.
- Background: PubMed 30446423McCarthy LM, Li S, Fernandes O, Cameron K, Lui P, Wong G, Pariser P, Farrell J, Luke MJ, Guilcher SJT. Enhanced communication between inpatient and community pharmacists to optimize medication management during transitions of care. J Am Pharm Assoc (2003). 2019 Jan-Feb;59(1):79-86.e1. doi: 10.1016/j.japh.2018.09.006. Epub 2018 Nov 13.
- Background: PubMed 28943987Bruhwiler LD, Hersberger KE, Lutters M. Hospital discharge: What are the problems, information needs and objectives of community pharmacists? A mixed method approach. Pharm Pract (Granada). 2017 Jul-Sep;15(3):1046. doi: 10.18549/PharmPract.2017.03.1046. Epub 2017 Aug 25.
- Background: PubMed 34971408Grandchamp S, Blanc AL, Roussel M, Tagan D, Sautebin A, Dobrinas-Bonazzi M, Widmer N. Pharmaceutical Interventions on Hospital Discharge Prescriptions: Prospective Observational Study Highlighting Challenges for Community Pharmacists. Drugs Real World Outcomes. 2022 Jun;9(2):253-261. doi: 10.1007/s40801-021-00288-x. Epub 2021 Dec 31.
- Background: PubMed 30136718Redmond P, Grimes TC, McDonnell R, Boland F, Hughes C, Fahey T. Impact of medication reconciliation for improving transitions of care. Cochrane Database Syst Rev. 2018 Aug 23;8(8):CD010791. doi: 10.1002/14651858.CD010791.pub2.
- Background: PubMed 26233535Ensing HT, Stuijt CC, van den Bemt BJ, van Dooren AA, Karapinar-Carkit F, Koster ES, Bouvy ML. Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review. J Manag Care Spec Pharm. 2015 Aug;21(8):614-36. doi: 10.18553/jmcp.2015.21.8.614.
- Background: PubMed 26908524Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016 Feb 23;6(2):e010003. doi: 10.1136/bmjopen-2015-010003.
- Individual participant dataSharing planned: Yes. Data to be shared includes demographic and study outcomes, with a data summary Data will be anonymized and shared in a secure format (CSV)
Related trials for Polypharmacy
Not yet recruiting
Impact of Pharmacotherapy Optimization in Polymedicated Lebanese Older Adults in Primary Health Care Centers
Older Adults (65 Years and Older), Polypharmacy (People Under Treatment With 5 or More Drugs)
Active, not recruiting
Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions
Prescribing Decisions, Diabetes
Recruiting
Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
Virus-HIV
Active, not recruiting
Improving Medication Management in World Trade Center Responders
Polypharmacy
Recruiting
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
Pharmacogenomic Drug Interaction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anne-Laure Blanc, PharmD, PhD study director
Pharmacie des Hôpitaux de l'Est Lémanique
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Support of the hospital pharmacist for the medication management at hospital discharge in people with Polypharmacy, run by Pharmacie des Hopitaux de l'Est Lemanique at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The trial was stopped prematurely after one year of recruitment because of a combination of slower-than expected enrollment, limited resources, and concerns regarding the feasibility of demonstrating the prespecified treatment effect.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of drug-related problems on the hospital discharge prescription (time frame: 7 days after hospital discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06902779, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.